Financials

Created on June 29, 2006, Ekkyo S.A. was supported at the beginning by the inter-university business incubator called “Impulse” and a €310 K subsidy from the French Ministry of Research as part of the 2006 competition promoting innovative companies.

In Q1 2007, the company raised €520 K from a first seed funding round with private investors in conjunction with several loans: Oseo ANVAR Innovation, Region for business development and research tax credits.

During the third term of 2008, the company raised €500 K following another seed funding round with private investors, among them Primaveris capital risk, that will be put towards launching an open-label, multicentric clinical trial and driving the market launch of EkkyLite™ in Europe.

With the goal of expanding its commercial reach in Europe and preparing the market launch of EkkyLite™ in the US, the company conducted a seed funding round at the end of 2008 and raised 2.3 M€. Sham a French health insurance company contributed up to 2 million euros to this funding. Long-standing investors and partners at Ekkyo have also contributed €300 k to this new round of funding (of which €200 k benefits from wealth tax deductions as part of the TEPA law intended to encourage investment in innovative companies).

With this funding round, Ekkyo will have raised €3.8 M in under only two years.

Ekkyo received subsidies from the French Ministry of Research, support for innovation from Oseo, research tax credit and a young innovating company status, not to mention technical support from business incubators… Together, these subsidies total about 1 million Euros.